CoChat

Precompetitive Consensus Building to Facilitate the Use of Digital Health Technologies to Support Parkinson Disease Drug Development through Regulatory Science

Open access
Stephenson, Diane, Alexander, Robert, Aggarwal, Varun, Badawy, Reham, Bain, Lisa, Bhatnagar, Roopal, Bloem, Bastiaan R., Boroojerdi, Babak, Burton, Jackson, Cedarbaum, Jesse M., Cosman, Josh, Dexter, David T., Dockendorf, Marissa, Dorsey, E. Ray, Dowling, Ariel V., Evers, Luc J. W., Fisher, Katherine, Frasier, Mark, Garcia-Gancedo, Luis, Goldsack, Jennifer C., Hill, Derek, Hitchcock, Janice, Hu, Michele T., Lawton, Michael P., Lee, Susan J., Lindemann, Michael, Marek, Ken, Mehrotra, Nitin, Meinders, Marjan J., Minchik, Michael, Oliva, Lauren, Romero, Klaus, Roussos, George, Rubens, Robert, Sadar, Sakshi, Scheeren, Joseph, Sengoku, Eiichi, Simuni, Tanya, Stebbins, Glenn, Taylor, Kirsten I., Yang, Beatrice, Zach, Neta, on behalf of the Critical Path for Parkinson’s Consortium · 2020 · Digital Biomarkers
Cited by 63

The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.

Abstract

Innovative tools are urgently needed to accelerate the evaluation and subsequent approval of novel treatments that may slow, halt, or reverse the relentless progression of Parkinson disease (PD). Therapies that intervene early in the disease continuum are a priority for the many candidates in the drug development pipeline. There is a paucity of sensitive and objective, yet clinically interpretable, measures that can capture meaningful aspects of the disease. This poses a major challenge for the development of new therapies and is compounded by the considerable heterogeneity in clinical manifestations across patients and the fluctuating nature of many signs and symptoms of PD. Digital health technologies (DHT), such as smartphone applications, wearable sensors, and digital diaries, have the potential to address many of these gaps by enabling the objective, remote, and frequent measurement of PD signs and symptoms in natural living environments. The current climate of the COVID-19 pandemic creates a heightened sense of urgency for effective implementation of such strategies. In order for these technologies to be adopted in drug development studies, a regulatory-aligned consensus on best practices in implementing appropriate technologies, including the collection, processing, and interpretation of digital sensor data, is required. A growing number of collaborative initiatives are being launched to identify effective ways to advance the use of DHT in PD clinical trials. The Critical Path for Parkinson’s Consortium of the Critical Path Institute is highlighted as a case example where stakeholders collectively engaged regulatory agencies on the effective use of DHT in PD clinical trials. Global regulatory agencies, including the US Food and Drug Administration and the European Medicines Agency, are encouraging the efficiencies of data-driven engagements through multistakeholder consortia. To this end, we review how the advancement of DHT can be most effectively achieved by aligning knowledge, expertise, and data sharing in ways that maximize efficiencies.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1159/000512500

Cites

12 of 12 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 12 references

Cited by

See all 63

Metadata

Authors
Stephenson, D., Alexander, R., Aggarwal, V., Badawy, R., Bain, L., Bhatnagar, R., Bloem, B. R., Boroojerdi, B., Burton, J., Cedarbaum, J. M., Cosman, J., Dexter, D. T., Dockendorf, M., Dorsey, E. R., Dowling, A. V., Evers, L. J. W., Fisher, K., Frasier, M., Garcia-Gancedo, L., Goldsack, J. C., Hill, D., Hitchcock, J., Hu, M. T., Lawton, M. P., Lee, S. J., Lindemann, M., Marek, K., Mehrotra, N., Meinders, M. J., Minchik, M., Oliva, L., Romero, K., Roussos, G., Rubens, R., Sadar, S., Scheeren, J., Sengoku, E., Simuni, T., Stebbins, G., Taylor, K. I., Yang, B., Zach, N., & on behalf of the Critical Path for Parkinson’s Consortium
Venue
Digital Biomarkers
Publisher
S. Karger AG
Published
2020-11-26
Volume
4
Issue
Suppl. 1
Pages
28-49
ISSN
2504-110X (ISSN-L)
OpenAlex
W3109533980
Cited by
63
References
12
FWCI
10.31
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Precompetitive Consensus Building to Facilitate the Use of Digital Health Technologies to Support Parkinson Disease Drug Development through Regulatory Science. https://app.cochat.ai/papers/10.1159/000512500
The paper
Stephenson, D., Alexander, R., Aggarwal, V., Badawy, R., Bain, L., Bhatnagar, R., Bloem, B. R., Boroojerdi, B., Burton, J., Cedarbaum, J. M., Cosman, J., Dexter, D. T., Dockendorf, M., Dorsey, E. R., Dowling, A. V., Evers, L. J. W., Fisher, K., Frasier, M., Garcia-Gancedo, L., . . . on behalf of the Critical Path for Parkinson’s Consortium. (2020). Precompetitive Consensus Building to Facilitate the Use of Digital Health Technologies to Support Parkinson Disease Drug Development through Regulatory Science. Digital Biomarkers. https://doi.org/10.1159/000512500

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.